Stockreport

ProKidney revises Phase 3 program for lead asset [Seeking Alpha]

ProKidney Corp. - Class A Ordinary Shares  (PROK) 
PDF The company said it has decided to discontinue its Phase 3 REGEN-016 (PROACT 2) trial for the candidate, noting that the trial, which was based on overseas patients, wi [Read more]